US20030099723A1 - Method for the prevention or treatment of hypomagnesemia in pediatric patients and in patients with g-tubes or ng-tubes - Google Patents
Method for the prevention or treatment of hypomagnesemia in pediatric patients and in patients with g-tubes or ng-tubes Download PDFInfo
- Publication number
- US20030099723A1 US20030099723A1 US09/988,104 US98810401A US2003099723A1 US 20030099723 A1 US20030099723 A1 US 20030099723A1 US 98810401 A US98810401 A US 98810401A US 2003099723 A1 US2003099723 A1 US 2003099723A1
- Authority
- US
- United States
- Prior art keywords
- magnesium
- tubes
- patients
- pharmaceutical composition
- bioavailable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 206010021027 Hypomagnesaemia Diseases 0.000 title claims abstract description 8
- 238000011282 treatment Methods 0.000 title description 4
- 230000002265 prevention Effects 0.000 title description 3
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 12
- QYOBXHXZJRPWDE-JIZZDEOASA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate;chloride Chemical compound [Mg+2].Cl.[O-]C(=O)[C@@H](N)CC([O-])=O QYOBXHXZJRPWDE-JIZZDEOASA-L 0.000 claims abstract description 7
- 235000014483 powder concentrate Nutrition 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 10
- 239000011777 magnesium Substances 0.000 claims description 29
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 28
- 229910052749 magnesium Inorganic materials 0.000 claims description 28
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004552 water soluble powder Substances 0.000 abstract description 2
- 229940091250 magnesium supplement Drugs 0.000 description 25
- 239000000203 mixture Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 2
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000296 active ion transport Effects 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003615 hypomagnesemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 238000009140 magnesium supplementation Methods 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Definitions
- the present invention relates generally to the prevention or treatment of hypomagnesemia in pediatric patients and in patients with gastric tubes (G-tubes) or nasogastric tubes (NG-tubes). More particularly, the present invention relates to the administration of a powder concentrate magnesium supplement via a G-tube or NG-tube to patients in need thereof. The present invention also allows for the easy administration of a magnesium supplement to pediatric patients in need thereof.
- G-tubes gastric tubes
- NG-tubes nasogastric tubes
- Magnesium is essential for all living organisms and is required for over 300 different metabolic processes. For example, magnesium helps regulate the release of insulin by facilitating the activation of a tyrosine protein kinase receptor. In hypomagnesemic patients, the ability of insulin to activate the protein kinase receptor is impaired, which results in reduced peripheral glucose uptake.
- magnesium is a calcium antagonist and displaces calcium from cellular membrane receptors and enzymatic binding sites.
- One such example is the competition between calcium and magnesium for binding sites of troponin C, which is involved in muscle contractions. When magnesium binds to this receptor, it effectuates a smaller conformational change than if calcium binds to the receptor.
- the sodium/potassium pump is the sodium/potassium pump.
- the driving force of this pump is a magnesium-dependant ATPase, which splits ATP. This in turn provides the energy needed for active ion transport.
- magnesium deficiency Due to its involvement in so many cellular processes, magnesium deficiency has been shown to be associated with several disease states, including Type I and Type II diabetes, hypertension, cerebral and myocardial infarctions, atheroschlerosis, osteoporosis, PMS (headaches, fluid retention and mood changes), muscle cramps, and bipolar disorder. Furthermore, many prescription medications deplete the body of magnesium. These include, but are not limited to: loop diuretics, Thiazide diuretics, Corticosteroids, Glycosides and Estrogens and Estrogen derivatives.
- the present invention provides an improved method for the prophylaxis and treatment of hypomagnesemia in pediatric patients and in patients with G-tubes and NG-tubes.
- the present invention provides an absorbable and bioavailable form of magnesium that can be effectively administered to pediatric patients and patients with G-tubes or NG-tubes in order to raise the blood levels of magnesium in such patients.
- the present invention provides a method for increasing the blood magnesium levels in pediatric patients and patients with G-tubes or NG-tubes by administering a magnesium salt in the form of a hygroscopic powder to patients in need thereof.
- the magnesium salt is magnesium-L-aspartate hydrochloride.
- the present invention provides a readily bioavailable and absorbable magnesium salt in the form of a concentrated powder that can be dissolved in water and easily administered to pediatric patients or administered to patients via a G-tube or NG-tube.
- the composition of the present invention includes a magnesium salt in the form of a water-soluble powder concentrate.
- the magnesium salt is magnesium-L-aspartate hydrochloride.
- magnesium-L-aspartate hydrochloride is in the form of granules and is comprised of, per dosing unit:
- Ingredient Amount Active Ingredient Magnesium-L-Aspartate HCl ⁇ 3H 2 O 1230.0 mg (equiv. to 121.53 mg of Mg)
- Excipients Sucrose 4484.0 mg Citric acid, anhydrous 170.0 mg
- the present invention also provides a method of raising magnesium blood levels in pediatric patients and patients with G-tubes or NG-tubes.
- the method includes the step of administering a bioavailable and absorbable magnesium composition having a magnesium salt in the form of a hygroscopic powder.
- the magnesium composition contains magnesium salt in an amount ranging from about 5 mEq to about 10 mEq.
- the magnesium composition is administered in a dosage ranging from about 122 mg/day to about 488 mg/day.
- An advantage of the present invention is that it provides a bioavailable and absorbable form of magnesium that may be administered enterally to patients with G-tubes or NG-tubes or orally to pediatric patients. This granule formulation provides an inherent advantage over the traditional tablet form for these patients.
- magnesium composition is acid-base neutral and does not interfere with the absorption of iron.
- an advantage of the present invention is that it has no undesirable side effects.
- magnesium composition is acid-base neutral and does not interfere with the absorption of iron.
- an advantage of the present invention is that it has no undesirable side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
A method of preventing or treating hypomagnesemia in pediatric patients and patients with G-tubes or NG-tubes comprising the step of administering a pharmaceutical composition comprised of a magnesium salt, magnesium-L-aspartate hydrochloride, in a water-soluble powder concentrate. When dissolved in water, the pharmaceutical composition provides a method for preventing or treating hypomagnesemia in such patients without compromising the absorption or efficacy of the pharmaceutical composition.
Description
- The present invention relates generally to the prevention or treatment of hypomagnesemia in pediatric patients and in patients with gastric tubes (G-tubes) or nasogastric tubes (NG-tubes). More particularly, the present invention relates to the administration of a powder concentrate magnesium supplement via a G-tube or NG-tube to patients in need thereof. The present invention also allows for the easy administration of a magnesium supplement to pediatric patients in need thereof.
- Magnesium is essential for all living organisms and is required for over 300 different metabolic processes. For example, magnesium helps regulate the release of insulin by facilitating the activation of a tyrosine protein kinase receptor. In hypomagnesemic patients, the ability of insulin to activate the protein kinase receptor is impaired, which results in reduced peripheral glucose uptake. In addition, magnesium is a calcium antagonist and displaces calcium from cellular membrane receptors and enzymatic binding sites. One such example is the competition between calcium and magnesium for binding sites of troponin C, which is involved in muscle contractions. When magnesium binds to this receptor, it effectuates a smaller conformational change than if calcium binds to the receptor. Finally, one the mechanisms responsible for cardiac muscle contraction is the sodium/potassium pump. The driving force of this pump is a magnesium-dependant ATPase, which splits ATP. This in turn provides the energy needed for active ion transport. These are only a few of the many examples of magnesium's role in the human body.
- Due to its involvement in so many cellular processes, magnesium deficiency has been shown to be associated with several disease states, including Type I and Type II diabetes, hypertension, cerebral and myocardial infarctions, atheroschlerosis, osteoporosis, PMS (headaches, fluid retention and mood changes), muscle cramps, and bipolar disorder. Furthermore, many prescription medications deplete the body of magnesium. These include, but are not limited to: loop diuretics, Thiazide diuretics, Corticosteroids, Glycosides and Estrogens and Estrogen derivatives.
- Patients taking magnesium-depleting medications are often advised to supplement with oral magnesium. Magnesium supplementation is difficult because the current magnesium formulations on the market have low bioavailability and are not readily absorbed. Furthermore, these supplements often cause diarrhea.
- One of the biggest problems, however, is the supplementation of pediatric patients, who are unable to swallow tablets, and patients with G-tubes or NG-tubes who are unable to take medication orally. Presently, health care providers must pulverize magnesium tablets to supplement pediatric patients and patients with G-tubes or NG-tubes. Not only is this process time consuming but it also compromises the absorption and efficacy of the product.
- Therefore, a need exists for an improved composition and method for the prevention and treatment of hypomagnesemia in pediatric patients and patients with G-tubes and NG-tubes.
- The present invention provides an improved method for the prophylaxis and treatment of hypomagnesemia in pediatric patients and in patients with G-tubes and NG-tubes. Particularly, the present invention provides an absorbable and bioavailable form of magnesium that can be effectively administered to pediatric patients and patients with G-tubes or NG-tubes in order to raise the blood levels of magnesium in such patients.
- The present invention provides a method for increasing the blood magnesium levels in pediatric patients and patients with G-tubes or NG-tubes by administering a magnesium salt in the form of a hygroscopic powder to patients in need thereof. Preferably, the magnesium salt is magnesium-L-aspartate hydrochloride.
- As stated above, there is presently no satisfactory method for the enteral administration of magnesium to patients with G-tubes or NG-tubes. In addition, there is no satisfactory method for the administration of magnesium to pediatric patients, who are unable to swallow tablets. Furthermore, existing magnesium formulations are poorly absorbed from the digestive tract. The present invention provides a readily bioavailable and absorbable magnesium salt in the form of a concentrated powder that can be dissolved in water and easily administered to pediatric patients or administered to patients via a G-tube or NG-tube.
- The composition of the present invention includes a magnesium salt in the form of a water-soluble powder concentrate. In an embodiment, the magnesium salt is magnesium-L-aspartate hydrochloride. In said embodiment, magnesium-L-aspartate hydrochloride is in the form of granules and is comprised of, per dosing unit:
Ingredient Amount Active Ingredient: Magnesium-L-Aspartate HCl · 3H2O 1230.0 mg (equiv. to 121.53 mg of Mg) Excipients: Sucrose 4484.0 mg Citric acid, anhydrous 170.0 mg Polyethylene glycol 6000 100.0 mg Dry lemon flavoring essence 16.0 mg Total weight: 6000.0 mg - The present invention also provides a method of raising magnesium blood levels in pediatric patients and patients with G-tubes or NG-tubes. The method includes the step of administering a bioavailable and absorbable magnesium composition having a magnesium salt in the form of a hygroscopic powder.
- In an embodiment, the magnesium composition contains magnesium salt in an amount ranging from about 5 mEq to about 10 mEq.
- In an embodiment, the magnesium composition is administered in a dosage ranging from about 122 mg/day to about 488 mg/day.
- An advantage of the present invention is that it provides a bioavailable and absorbable form of magnesium that may be administered enterally to patients with G-tubes or NG-tubes or orally to pediatric patients. This granule formulation provides an inherent advantage over the traditional tablet form for these patients.
- Another advantage is that the magnesium composition is acid-base neutral and does not interfere with the absorption of iron.
- Still further, an advantage of the present invention is that it has no undesirable side effects.
- Another advantage is that the magnesium composition is acid-base neutral and does not interfere with the absorption of iron.
- Still further, an advantage of the present invention is that it has no undesirable side effects.
Claims (9)
1. A method of treating hypomagnesemia comprising the step of administering via G-tube or NG-tube a therapeutically effective amount of a pharmaceutical composition, comprising a bioavailable and absorbable magnesium salt to a patient in need thereof.
2. The method of claim 1 , wherein said pharmaceutical composition contains about 10 milliequivalents of bioavailable magnesium.
3. The method of claim 2 , wherein said pharmaceutical composition is magnesium-L-aspartate hydrochloride.
4. A method of raising the blood magnesium levels in patients with G-tubes or NG-tubes comprising administering a therapeutically effective amount of a readily bioavailable and absorbable magnesium salt in the form of a powder concentrate.
5. The method of claim 4 , wherein said pharmaceutical composition contains about 10 milliequivalents of bioavailable magnesium.
6. The method of claim 5 , wherein said magnesium salt is magnesium-L-aspartate hydrochloride.
7. A method of treating hypomagnesemia and raising blood magnesium levels in pediatric patients comprising the step of administering a therapeutically effective amount of a pharmaceutical composition, comprising a bioavailable and absorbable magnesium salt to a patient in need thereof.
8. The method of claim 7 , wherein said pharmaceutical composition contains about 10 milliequivalents of bioavailable magnesium.
9. The method of claim 8 , wherein said pharmaceutical composition is magnesium-L-aspartate hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/988,104 US6579905B1 (en) | 2001-11-19 | 2001-11-19 | Method for the prevention or treatment of hypomagnesemia in pediatric patients and in patients with G-tubes or NG-tubes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/988,104 US6579905B1 (en) | 2001-11-19 | 2001-11-19 | Method for the prevention or treatment of hypomagnesemia in pediatric patients and in patients with G-tubes or NG-tubes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20030099723A1 true US20030099723A1 (en) | 2003-05-29 |
| US6579905B1 US6579905B1 (en) | 2003-06-17 |
Family
ID=25533863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/988,104 Expired - Fee Related US6579905B1 (en) | 2001-11-19 | 2001-11-19 | Method for the prevention or treatment of hypomagnesemia in pediatric patients and in patients with G-tubes or NG-tubes |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US6579905B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100415226C (en) * | 2005-03-23 | 2008-09-03 | 沈阳药联科技创新有限公司 | Electrolyte replenisher for treating hypopotassaemia hypomagnesemia and its uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4104370A (en) | 1974-07-10 | 1978-08-01 | Smith Kline & French Laboratories Limited | Method of treating magnesium/potassium depletion |
| DE2507354A1 (en) | 1975-02-20 | 1976-09-09 | Verla Pharm | PHARMACEUTICAL PREPARATION |
| US4137326A (en) | 1975-04-11 | 1979-01-30 | Verla-Pharm Arzneimittelfabrik, Apotheker H.J.V. Ehrlich | Use of magnesium monospartate hydrochloride complex |
| GB8308126D0 (en) | 1983-03-24 | 1983-05-05 | Bloch M | Pharmaceutical compositions |
| US4855289A (en) | 1984-06-04 | 1989-08-08 | Wester Per O | Combination of two active substances |
| US4954349A (en) | 1987-09-11 | 1990-09-04 | Ciba-Geigy Corporation | Oral magnesium and potassium compositions and use |
| DE3809625A1 (en) * | 1988-03-22 | 1989-10-05 | Verla Pharm | ORAL-AVAILABLE PHARMACEUTICAL AGENT, IN PARTICULAR FOR IRON AND MAGNESIUM SUBSTITUTION THERAPY |
| US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
| US5501859A (en) | 1994-03-22 | 1996-03-26 | Walter T. Woods, Jr. | Absorbable magnesium composition and method of using same |
-
2001
- 2001-11-19 US US09/988,104 patent/US6579905B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6579905B1 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2849792B1 (en) | Liquid formulation | |
| KR960011772B1 (en) | Oral dosing formulations of dideoxy purine nucleosides | |
| US8658206B2 (en) | Compositions comprising strontium and vitamin D and uses thereof | |
| HRP950293A2 (en) | Oral liquidalendronate formulations | |
| US11324696B2 (en) | Suspensions and diluents for metronidazole and baclofen | |
| US4387093A (en) | Arthritis treatment | |
| DK169605B1 (en) | Magnesium additive for food, feed and pharmaceuticals | |
| AU723357B2 (en) | Liquid alendronate formulations | |
| EP0719148B1 (en) | Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt | |
| US6579905B1 (en) | Method for the prevention or treatment of hypomagnesemia in pediatric patients and in patients with G-tubes or NG-tubes | |
| WO2000074685A1 (en) | Oral preparations of etidronate disodium | |
| US20090170815A1 (en) | Alendronate oral liquid formulations | |
| GB2619970A (en) | An orodispersible pharmaceutical composition of baclofen and its process of preparation | |
| US20220142920A1 (en) | Praziquantel Formulations | |
| JP2022032929A (en) | Pharmaceutical composition containing lanthanum carbonate for improving hyperphosphatemia associated with administration of anticancer agent | |
| WO2021262114A1 (en) | An orally disintegrating tablet formulation comprising sitagliptin | |
| WO2018204040A1 (en) | Oral liquid compositions of valsartan | |
| JP2003335703A (en) | Treating agent for hypertrophic pyloric stenosis and kit for the same | |
| KR20000048829A (en) | Liquid alendronate formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: BLAINE COMPANY INC. D/B/A BLAINE PHARMACEUTICALS, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCMAINS, MICHAEL B.;GEPPERT, CAREN D.;SIEGEL, MISSY L.;REEL/FRAME:015953/0489;SIGNING DATES FROM 20041004 TO 20041005 |
|
| AS | Assignment |
Owner name: LOGAN PHARMACEUTICALS LLC, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BLAINE COMPANY, INC. D/B/A BLAINE PHARMACEUTICALS;REEL/FRAME:016226/0971 Effective date: 20041221 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20070617 |